UBS initiated coverage of Incyte (INCY) with a Neutral rating and $77 price target The firm sees a balanced risk/reward amid the company’s diversification efforts beyond the core business.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY: